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Systemiclupuserythematosus(SLE)isacomplex autoimmune disorder,knowntohave a stronggenetic component. Concordance
between monozygotic twins is approximately 30–40%, which is 8–20 times higher than that of dizygotic twins. In the last decade,
genome-wide approaches to understanding SLE have yielded many candidate genes, which are important to understanding the
pathophysiologyofthediseaseandpotentialtargetsforpharmaceuticalintervention.Inthispaper,wefocusontheroleofcytokines
and examine how genome-wide association studies, copy number variation studies, and next-generation sequencing are being
employed to understand the etiology of SLE. Prominent genes identiﬁed by these approaches include BLK, FCγR3B, and TREX1.
Our goal is to present a brief overview of genomic approaches to SLE and to introduce some of the key discussion points pertinent
to the ﬁeld.
1.Introduction
Systemic lupus erythematosus (SLE) is a highly heteroge-
neous autoimmune disorder characterized by the prevalence
of autoantibodies directed against double-stranded DNA.
Small nuclear RNA-binding proteins, including anti-Ro,
anti-La, and anti-RNP are also found in many patients.
Worldwide, the prevalence is approximately 52 per 100,000
and may be highest among individuals of Afro-Caribbean
descent at 159 per 100,000 (derived from a UK sample) [1].
In the United States, SLE is 2.6 times more common in in-
dividuals of African as opposed to European descent (19.5
versus 7.4 per 100,000), reﬂecting a disproportionate ethnic
disease burden. For adult-onset SLE, the female:male ratio
is 9:1 [2].
SLE is underscored by a range of environmental and ge-
netic risk factors that can aﬀect any part of the organ system,
including cardiovascular, hematological, integumentary,
musculoskeletal, nervous, renal, and respiratory. In this pa-
per, we focus on three major approaches that are being used
to uncover genetic correlates of the disease, genome-wide
association studies (GWAS), copy number variation (CNV)
studies, and next-generation sequencing (NGS). Our goal is
to provide a brief overview of the genomic landscape and
to introduce some of the key discussion points in terms of
how these approaches inform our understanding of SLE,
particularly in relation to cytokines. To date, more than 40
relevant loci have been identiﬁed and replicated; many of
which directly or indirectly involve cytokines regulation.
Cytokines are important components of immune res-
ponse and regulation and play an active role in activating,
diﬀerentiating, and maturing immune cells [6]. An imbal-
ance between pro- and anti-inﬂammatory cytokines is a well
known characteristic of SLE [7]. They are heavily integrat-
edinT-CellandB-Cellsignalingsystemsandabnormalcyto-
kine levels, particularly interleukins, interferons, and tumor
necrosis factors (TNFs), are important hallmarks of SLE.
2. Genome-WideAssociation Studies
Genome-wideassociationstudiesbegantoproliferateappro-
ximately 6 years ago, coinciding with rapid developments in
genomic hardware and software and falling costs of relevant
technologies.GWASusemicroarraystotaguptoseveralmil-
lion single nucleotide polymorphisms (SNPs) at once, which2 Journal of Biomedicine and Biotechnology
gives broad coverage of exonic and intronic regions (though
coverage is weighted toward the former). When a diﬀerence
in SNP-frequency is observed between cases and controls, we
can infer a diﬀerence in the underlying genomic locus, which
mayaﬀectgene expression or regulation. Because of the large
number of comparisons being made, most GWAS require
very large numbers of patients and controls and sample sizes
in excess of several thousand are the norm.
Table 1 lists the ∼40 loci that have been associated with
SLE by GWAS. A number of these genes, particularly in the
human leukocyte antigen (HLA) complex, were identiﬁed
beforethegenomeera.SincethepublicationoftheﬁrstGWA
study into SLE in 2007, this list has expanded rapidly and
at least nine GWAS have been published [8–16]. Prominent
replicated genes are discussed below. A major beneﬁt of the
GWA approach is its applicability to complex disease.
3. HLARegulation
The HLA system/histocompatibility complex (MHC) has
long been associated with SLE. Because of its long-stand-
ingimportancetoimmunefunction[17],thecompleteHLA/
MHC was one of the ﬁrst multigenic regions of the human
genome to be sequenced [18]. It is densely packed with genes
that regulate immune functions and all of the GWAS of
SLE converge upon the region as the strongest predictor of
genetic risk [12–16]. HLA genes are classiﬁed as types I, II,
and III, and the region also includes a number of genes that
encodetumornecrosisfactorα(TNF-α)cytokines,whichare
discussed separately below. The class II and class III regions
have been most closely associated with SLE.
3.1. HLA Class II. Genes belonging to HLA Class II are
prominent candidates for SLE susceptibility and are known
to play a major role in T-cell immunity. Graham et al. [19]
diﬀerentiated three haplotypes in the region that are asso-
ciated with SLE risk. More speciﬁcally, the DR beta 1 gene
(HLA-DRB1) has been shown to associate with SLE across a
range of ethnic populations, though the speciﬁc risk to each
population varies by haplotype and serotype [20, 21].
The DR2 (DRB1∗1501) serotype [22]a sw e l la sD R 3
(DRB1∗0301) holds the strongest evidence of association
[23]. Recently, GWAS have conﬁrmed these associations in
EuropeanandAsianpopulations[11,24].HLAClassIIgenes
including HLA-DRB1 a r ea l s oam a j o rc o m p o n e n to fT - C e l l
signaling networks, and they present relevant peptides for
recognition by T-Cells. Comparing anti-dsDNA-negative
SLE versus healthy controls, Chung et al. [9] found a signiﬁ-
cantassociationforaSNP,rs2301271,9kbdownstreamfrom
HLA-DQA2 (P = 2 × 10
−12). The authors point out that
extensive linkage disequilibrium in this region may attribute
the association to the HLA-DRB1 locus. The same study
found a strong association between anti-dsDNA and HLA-
DR3 at rs2187668. Further, the association with SLE was
found to be far stronger in anti-dsDNA-positive SLE versus
either anti-dsDNA-negative or the SLE phenotype. This
important ﬁnding suggests that the HLADR3 allele is most
closely aligned to the production of autoantibodies per se,
Table 1: Loci associated with SLE from GWAS. Table adapted from
http://www.genome.gov/gwastudies/. Anumberofthese genes were
associated with SLE prior to GWAS and have now been replicated,
whileothersawaitreplication.Intergenicregionsarelistedinbrack-
ets. It is important to note that many genes associated with SLE in
individuals of European ancestry are not associated with the disease
in Asian populations, with the converse also holding true. Similar
diﬀerences in susceptibility are certain to be found between other
populations for whom the requisite GWAS have not yet been con-
ducted.AsBustamanteetal.[3]andothershavepointedout,indivi-
duals of European ancestry are heavily overrepresented in GWAS,
and many more comparison studies are needed to address this sam-
pling bias.
Region Reported gene(s) Reported OR Population
1p31.1 NEGR1 EU7
1p32.3 SLC1A7 1.32 EU1
1q25.1 TNFSF4 1.22–1.46 AS4,E U 6
1q25.3 LAMC2 1.33 EU1
1q31.1 IL10 [RPS3AP9-FAM5C] 1.19–1.3 EU1,9
2p16.3 [FSHR-RPL7P13] NR EU5
2p22.3 RASGRP3 1.43 AS4
2q31.3 [CWC22-FTHL20]1 . 7 2 E U 1
2q32.3 STAT4 1.41–1.77 AS4,E U 1,5,7
3p14.3 PXK 1.25 EU6
3q26.31 NAALADL2 1.37 EU1
3q26.32 [ASS1P7-KCNMB2]1 . 5 6 E U 1
4q24 BANK1 1.38 EU8
4q25 COL25A1 1.33 EU1
4q28.3 [PCDH18-SLC7A11]E U 5
5p13.1 GHR EU7
5q33.1 TNIP1 1.23–1.27 AS4,E U 9
5q33.3 PTTG1 1.32 EU1
6p21.31 UHRF1BP1 1.17 EU9
6p21.32
HLA region
HLA-DQA1
HLA-DQA2
HLA-DR3,
HLA-DRB1
NOTCH4
C6orf10
TNXB
1.38–2.36 AS1,E U 1,6,7
6q21 PRDM1
ATG5 1.20–1.25 AS4,E U 9
6q23.3 TNFAIP3 1.72–2.28 AS4,E U 5
7p12.2 IKZF1 1.39 AS4
7p15.1 JAZF1 1.19 EU9
7q32.1 IRF5
TNPO3 1.43–1.92 AS4,E U 1,6,7
8p23.1
BLK
FAM167A-BLK
C8orf13
1.29–1.45 AS4,E U 1,5,7
9q34.13 NTNG2 EU7
10q11.23
LRRC18
WDFY4
c10orf64
1.24–1.30 AS3,4,E U 5Journal of Biomedicine and Biotechnology 3
Table 1: Continued.
Region Reported gene(s) Reported OR Population
11p15.5 KIAA1542 1.28–1.33 EU1,6
11q11 OR4A15 1.92 EU1
11q24.3 ETS1 1.29–1.37 AS3,4
12q21.2 RPL7AP59 1.28 EU1
12q24.33 SLC15A4 1.26 AS4
13q14.11 ELF1 1.26 AS2
16p11.2 ITGAM
ITGAX 1.33–1.80 EU1,5,6,7
17p12 [HS3ST3A1-CDRT15P]E U 5
18q22.3 SOCS6 EU7
20p13 TMC2 1.37 EU1
22q11.21 HIC2
UBE2L3 1.28–1.38 AS4,E U 1
1Chung et al. [9] (NOTE: reported associations are for anti ds-DNA auto-
antibody production); 2Yang et al. [10]; 3Yang et al. [11]; 4Han et al. [12];
5Grahametal.[13]; 6Harleyetal.[14]; 7Hom et al. [15]; 8Kozyrev et al. [16];
9Gateva et al. [24]. A study by Li et al. (2011) did not report any signiﬁcant
associations. NOTE: The study by Gateva et al. [24]( 9)w a sn o tg e n o m e
wide, having used SNPs from 2,466 regions that showed nominal evidence
of association to SLE (P<0.05).
rather than SLE in general. This was also true of observed
associations with STAT4, IRF5,a n dITGAM, which are dis-
cussed further below.
3.2.HLAClassIIIandtheComplementSystem. Thestrongest
single genetic risk factors of SLE are complement defects,
particularly a complete deﬁciency of the C1q immune com-
plex which, when present, is associated with a 93% risk of
SLE [25]. Related complement defects in C4, C1r/s, and (to
a lesser extent) C2, and C3 are ﬁrmly established as risk fac-
tors, with a prevalence of 75%, 57%, 32%, and 10%, respec-
tively [26, 27]. These deﬁciencies are diﬀerent from most
candidate variants in that they are strong predictors if
present. However, they are collectively rare, found in only 1-
2% of cases [28]. Dunckley et al. [29] reported a signiﬁcant
increase in the C4A null allele (C4AQ0) in Chinese, Euro-
pean, and Japanese populations compared to controls. In a
study of Japanese SLE patients, two SNPs in the C3 gene,
rs7951 and rs2230201, have also been signiﬁcantly associated
with increased disease risk, with the former correlating with
lower C3 serum levels [30].
The Class III gene, mutS homolog 5 (MSH5) gene, has
been associated with SLE and was in fact the strongest asso-
ciation in the GWAS by Harley et al. [14]. MSH5 facilitates
DNA rearrangements, which cause immunoglobulin class
switching [31]. Super viralicidic activity 2-like (SKIV2L)i s
another Class III gene previously identiﬁed as an SLE candi-
date, and a study of 314 trios from the United Kingdom [32]
implicatedthislocusindependentofclassIIvariants.SKIV2L
is a putative RNA helicase and is expressed in T cells, B cells,
anddendriticcells[32].TheintegrinalphaMgene(ITGAM)
has also been associated with SLE by a number of stud-
ies [9, 11, 14, 15]. Along with the β2 chain (ITGB2)
protein, ITGAM forms a leukocyte integrin, complement
receptor 3 (CC3), that facilitates adhesion of neutrophils
and monocytes to the stimulated endothelium. ITGAM is
also a receptor for the degraded CC3—iC3b [33]. Similarly,
missense mutations in Fcγ r e c e p t o r s( s e eb e l o w )h a v eb e e n
shown to disrupt inﬂuence immune complex processing
[34].
4. Tumor Necrosis Factor α
The tumor necrosis factor α (TNF-α) family of cytokines
havebeenrepeatedlyassociatedwithSLE,thoughthespeciﬁc
role of TNF is still debated. As discussed further below, the
interleukin, IL-10 is known to suppress TNF-α and the theo-
retical relationship between the two is illustrated in Figure 1.
TNF-α plays an important role in autoimmune regulation
and is a primary mediator of the response to infectious
organisms. TNF-α is primarily activated by mononuclear
phagocytes but is also secreted by Nκ cells, T cells, and mast
cells [35]. Although TNF-α plays a prominent role in ﬁght-
ing infection, excessive levels of this cytokine have been asso-
ciated with a number of autoimmune diseases including
Crohn’s disease, multiple sclerosis, and rheumatoid arthritis
[36]. Treatment with anti-TNF medication has been pro-
posed as a treatment for SLE [37] and is an active therapy
forotherautoimmunediseases,presumablybyregulatingthe
production of IFN-α by pDC [38].
4.1. TNFSF4. TNF ligand superfamily 4 as well and its re-
ceptor, TNFRSF4, are primarily expressed on activated anti-
gen-presenting cells [39]a n da c t i v a t e dC D 4 +Tc e l l s[ 40],
respectively. Graham et al. [41] used family-based and case-
control approaches to identify a risk allele upstream of
TNFS4 that predisposes to SLE and is correlated with in-
creased TNFSF4 expression. The authors hypothesized that
increased expression of TNFSF4 enhances interactions with
either antigen-presenting cells or modulating T-cell activa-
tion. Recent GWAS [12, 24] have conﬁrmed the association
in European and Chinese samples. A recent study by Sanchez
et al. [42] which targeted this and 15 other SLE-associated
locifoundthatSLErenaldisorderwassigniﬁcantlycorrelated
with risk alleles in ITGAM and TNFSF4. Similar associations
were found for ITGAM-discoid rash, STAT4-protection from
oral ulcers, and IL21- hematological disorder and suggest
ways in which genetic proﬁling may be used to predict SLE
etiology.
4.2. TNFAIP3. Graham et al. [13] used whole-genome asso-
ciation to identify a signiﬁcant relationship between tumor
necrosis factor, alpha-induced protein 3 (TNFAIP3), and
SLE, with the SNP rs5029939 the primary correlate. Sub-
sequent GWAS [12, 24] replicated this association in Asian
populations. A number of polymorphisms in TNFAIP3 have
been associated with increased susceptibility to SLE [43, 44].
Recently, Adrianto et al. [45] identiﬁed a deletion (T) fol-
lowed by a transversion (T to A) that resulted in reduced
mRNA and A20 expression. By resequencing TNFAIP3 in af-
fected European and Korean samples, the authors were able
to compare nine risk variants at a signal locus. They found4 Journal of Biomedicine and Biotechnology
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Figure 1: Feedback loops between IL10 and TNFα-simpliﬁed model (from L´ opez et al. [4]). Th1 cells produce TNFα, which activates
dendritic cells, other antigen presenting cells (APCs) and induces IL-10 production. TNFα also promotes inﬂammation and apoptosis, gen-
erating neoantigens that can produce autoantibodies. Conversely, IL-10 antagonizes Th1 diﬀerentiation and inhibits APCs and T cells. IL-10
strongly stimulates B-cell proliferation, diﬀerentiation, and antibody production. As such, B-cell activation in the presence of neoantigens
may cause autoantibodies to be secreted and lead to tissue damage. Stat is a signal transducer and transcription activator.
that only one (the TT to A polymorphism) showed major
overlap with regulatory elements, which was therefore estab-
lished as the functional polymorphism driving the associa-
tion between TNFAIP3 a n dS L E .T h i si sap r i m ee x a m p l eo f
howGWASandNGSapproachescanbeusedincombination
to gain a deeper perspective on pathogenesis and is discussed
further below.
4.3. TNIP1. TNFAIP3-interacting protein 1 (TNIP1)i sa
closely related gene, also identiﬁed by GWAS as signiﬁcantly
associated with SLE [12, 46, 47]i nb o t hE u r o p e a na n d
Chinese populations. Both TNFAIP3 and TNIP1 regulate the
NF-κB signaling pathway, which is critical to the immune
response and is activated by TNF-α as well as other diverse
stimuli[48].ThemechanismsbywhichTNIP1andTNFAIP3
regulate NF-κB signaling are not fully understood, though
Heyninck and Beyaert [49] found that sequential deubiqui-
tination and ubiquitination of the TNF receptor-interacting
protein (RIP) may mediate this process. Gregersen and
Olsson [50] discuss a common pathway linking TNFAIP3,
TRAF1, TRAF2, CD40,a n dc-Rel in autoimmunity.
5. Interferon Cytokines
Interferons (IFNs) derive their name from their ability to
“interfere” with the host cells of viruses during the infectionJournal of Biomedicine and Biotechnology 5
process and have been heavily associated with the pathogen-
esis of SLE. Type I interferons include IFN-α (produced by
leukocytes) and IFN-β (produced by ﬁbroblasts), both of
which signal through the same receptor. IFN-α links the in-
nate and adaptive immune systems and is therefore a critical
component of the autoimmunity. A number of genes involv-
ed in IFN regulation have been associated with SLE, and
individuals who have received treatment for other disorders
using IFN-α supplementation have been known to develop
SLE [51], which has also been found to resolve following
discontinuationofIFN-α[52].Arecentstudy[53]ofAfrican
American (n = 387), European American (n = 516), and
Hispanic American (n = 186) patients found a strong asso-
ciation between SLE-associated autoantibodies and high IFN
activity for all ancestral backgrounds, though non-European
Americans have higher serum IFN activity.
5.1. IRF5. Interferon regulatory factor 5 (IRF5)i so n eo fa
family of nine IRFs, at least three of which have been associ-
atedwithSLE.IRF5isaparticularlystrongcandidatebecause
it can induce transcription of IFN-α mRNA [54]. Graham
et al. [55] identiﬁed an association between the rs2004640
SNPandSLE,andthislocushassubsequentlybeenreplicated
by GWAS in individuals of European, African and Asian
ancestry [46, 56–62]. Many functional variants have been
identiﬁed, including SNPs at the ﬁrst intron (rs2004640) and
at the 3  untranslated region (rs10954213 [46]), a ﬁve base-
pair insertion-deletion proximal to the 5  prime UTR [63]
and a 30bp [51] in the sixth exon. Haplotypes derived from
combining these variants are associated with varying degrees
of SLE risk, although linkage disequilibrium makes it dif-
ﬁcult to disentangle the functional impact of speciﬁc var-
iants. Niewold et al. [62] examined a risk haplotype con-
taining a number of functional elements at this locus and
found evidence of an increased risk for SLE, which is also
associatedwithhigh-serumIFN-α.Thestudyalsofoundthat
theincreasedserumIFN-αwascontingentuponthepresence
of anti-dsDNA and anti-RNA-binding protein autoantibod-
ies, which may support a “gene + autoantibody = high IFN-
α” model. Similar to their ﬁndings in relation the MHC
locus, Chung et al. [9] showed that GWA threshold levels for
anti-dsDNA-negative SLE had lower odds ratios and higher
P values compared to associations with anti-dsDNA-positive
SLE. While IRF5 is not an autoantibody susceptibility locus
perse,theauthorsconcludethatthislocusmayhaveastrong-
er eﬀect in anti-dsDNA-positive SLE. L¨ ofgren et al. [64]
recently genotyped IRF5 using the CGGGG insertion/de-
letion and the rs2004640, rs2070197, and rs10954213 SNPs
in 1488 SLE patients and 1466 healthy controls. This showed
that the rs10954213 is the main SNP responsible for altered
IRF5 expression in PBMC peripheral blood mononuclear
cells (PBMC).
5.2.IRF7. Theinterferonregulatoryfactor7(IRF7)genecan
also stimulate induction of IFN-α RNA [65]. Harley et al.
[14] identiﬁed a signiﬁcant association between SLE risk and
locus between IRF7 and the PHRF1 (PHD and ring ﬁnger
domains 1) gene in a European population. Similar to
the approach taken with the IRF5 haplotype above, the
Niewold group [66] examined the relationship between this
locus,thepresenceofserumIFN-α,andthepresenceofauto-
antibodies. Again, IFN-α was only observed in the presence
of speciﬁc autoantibodies. Furthermore, when the risk IRF5
and IRF7 genotypes were examined together, an additive
eﬀect was observed upon IFN-α that was not found in the
autoantibody-negative group.
5.3. IRF8. The GWA replication study by Gateva et al. [24]
highlighted a third member of the interferon regulatory fac-
tor family, IRF8, which is also an associated risk factor for
SLE. A diﬀerent variant at the same locus has also been asso-
ciated with multiple sclerosis [67], adding further weight to
this region as a potentially important region in relation to
autoimmune susceptibility. Hikami et al. [68] found that a
functional polymorphism in the 3 -untranslated region of
SPI1, known to regulate expression of IRF2, IRF4,a n dIRF8
[69, 70] is associated with increased risk of SLE.
5.4. STAT4. Kariuki et al. [71] identiﬁed an association bet-
ween a signal transducer and activator of transcription 4
(STAT4) risk allele (the T allele at rs7574865), which is asso-
ciated with lower serum IFN-α activity and increased sensi-
tivity to IFN-α signaling. Remmers et al. [72]r e p o r t e da n
association between signal transducer and activator of trans-
cription 4 (STAT4) and SLE (as well as rheumatoid arthritis).
Again, the association with SLE has since been replicated
i nan u m b e ro fG W A Si nE u r o p e a na n dA s i a np o p u l a t i o n s
[12–14, 24]. It represents one of six primary members of the
STAT family, all of which play important roles in cytokine
signaling. STAT4 is integral to IL-12 signaling in both T and
Nκ Cells and increases the production of IFN-γ and diﬀeren-
tiation of CD4 T Cells [73]. After it binds to the IL-12 recep-
tor, phosphorylated STAT4 forms homodimers, which trans-
locate to the nucleus and initiate transcription of genetic
targets, IFN-γ is amongst them [74]. The SNP rs7574865
in the third intron of STAT4 that is the most strongly asso-
ciated SNP and is also associated with an alternate SLE
phenotype that is more severe has a younger age of onset
(<30 years) and is characterized by characterized by double-
stranded DNA autoantibodies [75]. This SNP also correlates
with increased sensitivity to IFN-α [71]. The GWA study by
Chung et al. [9] conﬁrms an association between rs7574865
and anti-dsDNA-positive autoantibody production in SLE
(P = 2×10
−20). Indeed associations between STAT4 and this
phenotype were found to be stronger than with SLE per se.
As such, the authors suggest that STAT4 be considered an
autoantibody-propensity locus as opposed to and SLE-sus-
ceptibility locus. This claim is also made for the ITGAM and
HLA-DR3 loci.
Namjou et al. [75] identiﬁed three major STAT4 haplo-
types that were highly signiﬁcant in Europeans and mod-
erately signiﬁcant in Korean and Hispanic samples. Inter-
estingly, Sigurdsson et al. [76] report that the STAT4 SNP,
rs7582694, correlates with the production of anti-double-
strandedDNAantibodiesandhaveamultiplicativeriskeﬀect
of 1.82 with two independent IRF5 risk alleles. This provides6 Journal of Biomedicine and Biotechnology
a strong indication that interactions between the two genes
contribute to the pathogenesis of SLE. However, a study us-
ing 30 tagged SNPs by Abelson et al. [77] revealed no signi-
ﬁcant interaction eﬀects between SNPs in STAT4 and IRF5
and suggests that an additive model may most closely des-
cribe their combined contribution to SLE risk.
6.Interleukins
As a major component of the immune system, interleukins
are strongly linked to the pathophysiology of SLE, and genes
that encode interleukin proteins have been widely examined
as possible SLE susceptibility candidates. Interleukin (IL)-
10, which is an important immunoregulator that inhibits T-
cellfunctionandsuppressesproinﬂammatorycytokinessuch
as TNFα, IL-1, IL-6, IL-8, and IL-12 [78, 79] is particularly
important in this regard.
6.1.IL10. AGWAreplicationstudybyGatevaetal.[24]c on-
ﬁrmed an association between a SNP (rs3024505) on IL10
and SLE in individuals of European ancestry (P = 3.95 ×
10
−8). This followsup on a number of smaller scale studies
that have previously identiﬁed an association between SLE
and polymorphisms in IL10 [80, 81]( n = 58 and 158 resp.).
It is also consistent with a large-scale association study in an
Asian sample (n = 554) [82], which used six IL-10 promoter
SNPs to identify six haplotypes. The authors found an asso-
ciation between one of the haplotypes and decreased IL-10
production and also observed a dose-dependent eﬀect of the
microsatellite IL10. G as a signiﬁcant risk factor. IL10 is also
known to promote B-cell functions by facilitating antibody
production, diﬀerentiation, and proliferation [83]. Increased
production of IL-10 by peripheral B cells has been shown
to correlate with SLE severity [84]. Relevant polymorphisms
include the SNP rs1800896, which is characterized by a
glycine/alanine substitution at position −1082, rs1800871
(−819C/T), and rs1800872 (−592C/A) [4], all of which have
been shown to aﬀect IL-10 production [85–87]. Summers
et al. [88] showed that the ATA haplotype, speciﬁcally the
−592A allele, was more frequent in 23 cases of sudden infant
deathsyndrome,suggestingthatirregularlower/higherIL-10
production may aﬀect production of inﬂammatory cyto-
kines.
Anumberofothergenesthatencodeinterleukinproteins
have also been associated with SLE. IL18 that has long been
touted as an SLE candidate, though a recent dense mapping
of the locus failed to ﬁnd any evidence of a common variant
association[89].ArecentCNVstudyof938SLEpatientsand
1,017 healthy controls by [90]f o u n dah i g h e rp r o p o r t i o no f
copy number ampliﬁcations of IL17F, IL21,a n dIL22 in cases
(see below). Elevated expression of IL21 (4q26-q27), which
shows homology with genes that encode IL2, IL4, and IL15,
has been demonstrated in the sera of SLE cases and mouse
models [91]. Further work is needed to clarify the roles of
these and other interleukin coding genes in SLE. A thorough
review of SLE/interleukins is provided by L´ opez et al. [4].
6.2. IRAK1/MECP2. IL-1 receptor-associated kinase 1
(IRAK1) is part of the Toll/interleukin-1 receptor and
nuclear NFκ signaling pathway and has been associated with
both adult- and pediatric-onset SLE [92]. However, the
neighboringlocus,methyl-CpG-bindingprotein2(MECP2),
which is in strong linkage disequilibrium with IRAK1 and
is involved in regulating methylation-sensitive loci [93], has
also been proposed as the source of this signal [94], though
the two are not necessarily mutually exclusive. GWA by
Graham et al. [13] identiﬁed the IRAK1-MECP2 locus as
signiﬁcantly associated with SLE risk in Europeans, replicat-
ing a previous ﬁnding by Sawalha et al. [95].
7. B-Cell Signaling
Although B cells have been strongly associated with SLE, a
direct relationship between candidate genes and susceptibil-
ity has been diﬃcult to determine. However, GWAS have
facilitated the identiﬁcation of a number of variants involved
in B-cell signaling that may predispose to SLE. The most
prominent is B lymphocyte kinase (BLK), which is located
at 8p23.1. GWAS by Han et al. [12], Harley et al. [14], and
a replication study by Gateva et al. [24] identiﬁed this locus
as strongly associated with SLE risk in European and Asian
populations. BLK is a tyrosine kinase that transduces signals
downstream of the B-cell receptor and can phosphorylate
inhibitory Fc receptors on B cells [52]. A meta-analysis by
Fan et al. [96] utilizing 11,000+ cases and 20,000+ controls
from European and Asian populations examined the risk
alleles of rs13277113 and rs2248932. For the former, BLK
mRNAexpressionwas ∼50%lowerinAhomozygotesthanG
allele homozygotes. Similarly, at rs2248932, the C allele was
associated with lower levels of BLK mRNA, with C homozy-
gotes having ∼30% lower expression levels than T allele
homozygotes. Both the A allele of rs13277113 and the T
allele of rs2248932 were conﬁrmed as signiﬁcant risk fac-
tors for SLE. Similar to ﬁndings in relation to the MHC,
STAT4, ITGAM,a n dIRF5, the GWA study of anti-dsDNA
autoantibody production by Chung et al. [9]f o u n de v i d e n c e
of an association between this phenotype and BLK but did
not meet threshold criteria for genome-wide signiﬁcance.
7.1. BANK1. AG W As t u d yb yK o z y r e ve ta l .[ 16]i d e n t i ﬁ e d
an o n s y n o n y m o u sS N Pa m o n gaS w e d i s hp o p u l a t i o ni n
the B-cell scaﬀold protein with ankyrin repeats 1 (BANK1)
gene at rs10516487 (R61H), which was replicated in four
independent case-control sets. A study from our group con-
ﬁrmed this association in both European (n = 178) and
African American (n = 148) populations [97]. Although a
number of GWAS have not found a signiﬁcant association
with this locus, a large study of 1,724 SLE patients and
2,024 healthy controls of African American descent did
replicate BANK1 as an SLE candidate in this cohort (as
well as C8orf13-BLK, TNFSF4, KIAA1542,a n dCTLA4)[ 98].
Kozyrev et al. [16] identiﬁed two other nonsynonymous
SNPs at rs17266594 (intronic) and rs3733197 (A383T),
which have yet to be replicated as conﬁrmed SLE risk factors.
BANK1 has also been associated anti-dsDNA-positive but
not anti-dsDNA-negative autoantibody production in SLE
[9].Journal of Biomedicine and Biotechnology 7
8. T-Cell Signaling:CandidateGenes
Cytokines areusuallygrouped in accordancewith their func-
tional capacity as T helper (Th) Th1, Th2, and Th17. Over-
production of Th1 and Th17 most often results in T-cell
hyperactivity, whereas the overproduction of Th2 is linked
to hyperactive B Cells and humoral responses [35].
8.1. PTPN22. Protein phosphatase nonreceptor type 22
(PTPN22) is known to inhibit T-Cell activation [99]. It has
been associated with a wide range of autoimmune disorders
andinitiallycametoprominenceasacandidategenefortype
1 diabetes [100]. Indeed, as Gregersen and Olsson [50]p o i n t
out, the association between PTPN22 and a wide range of
phenotypes (including Graves’ disease [101–103], Hashi-
moto thyroiditis [104], myasthenia gravis [105], systemic
sclerosis [106], generalized vitiligo [107], Addison’s disease
[108], alopecia areata [109], juvenile idiopathic arthritis
[110–112], and SLE [14, 15]) provided one of the earliest
indications of a shared pathophysiology for many autoim-
mune disorders. In spite of this, however, it is notable that
PTPN22 risk alleles are not a universal feature of all auto-
immune diseases, and indeed the 1858 T autoimmune risk
allele is associated with protection against Crohn’s disease
[113]. Kariuki and Niewold [114] point out that this same
risk allele is associated with TNF-α-related diseases but not
with multiple sclerosis (treated with a related interferon,
IFN-β). This suggests a possible relationship between
PTPN22 and cytokine proﬁle, albeit at a secondary level. The
rs2476601 SNP polymorphism (cysteine to threonine,
C1858T) in the Lyp protein is signiﬁcantly associated with
the underactivation of both T and B Cells and deregulated
cytokine production [115, 116].
GWAS by Harley et al. [14] and replication by Gateva
et al. [24] identiﬁed a positive association between the
PTPN22 SNP, rs2476601, and SLE in European populations,
but a similar association has not been observed in the Asian
GWAS reviewed here. Deng and Tsao [117] point out that
this diﬀerence may be attributable to more variability in
European populations that may be between 2–15% [50].
PTPN22 has also been associated with anti-dsDNA-positive
but not anti-dsDNA-negative autoantibody production in
SLE [9].
8.2. PPP2R2B. Although not speciﬁcally identiﬁed by the
GWAS listed in Table 1, protein phosphatase 2, regulatory
subunit Bβ (PPP2R2B) may be important to SLE pathogene-
sis. A recent study by Crisp´ ın et al. [118] found that the regu-
latory Bβ that is expressed in resting human T cells is down-
regulated during T-cell activation and is upregulated by
interleuikin-2 (IL-2). In a study of SLE patients, the group
found that levels of PP2A Bβ were not increased by IL-2 de-
privation in 7 of the 14 cases, and this phenomenon was
paralleled by resistance to apoptosis. Furthermore, follow-
ing IL-2 withdrawal in T cells, levels of Bβ in these pa-
tients remained unchanged. This contrasts markedly with
responses from healthy controls as well as the remaining SLE
(nonapoptosis-resistant) patients, who demonstrated an
approximate threefold increase in Bβ. It would therefore
appear that, at least in a subset of SLE patients, Bβ may be
a primary cause of apoptosis resistance in T cells.
9. Fcγ Receptors
The fragment crystallizable (Fc) region is found at the tail of
antibody proteins. Fc receptors are involved in clearing the
immune complex and include Fcα,F c ε,a n dF c γ. The latter
has been most closely linked to the SLE susceptibility, with
an u m b e ro fl o w - a ﬃnity Fc receptors for immunoglobulin
G (IgC) identiﬁed as SLE candidates. These include FCγR2A,
FCγR2B, FCγR3A,a n dFCγR3B, all of which are regulated by
cytokines, including IL-4, IL-10 or TGF-β [119]. Cytokine-
mediated regulation of FcR expression is cell type-speciﬁc;
however, IL-4 upregulates FCγR2B expression in myeloid
cells but downregulates it in activated B cells [120]. One
should bear in mind that, particularly with earlier studies,
low coverage of Fcγ receptors by commercial manufacturers
(i.e., Aﬀymetrix and Illumina) has been an issue. This is
mainlyduetothepresenceofhomologoussequenceparalogs
at this locus [121].
9.1. FCγR2A. The nonsynonymous SNP, rs1801274 in the
FCγR2A ( F cf r a g m e n to fI g G ,l o wa ﬃnity IIa, receptor) gene
has been associated with reduced clearance of immune com-
plexes, where the (C) allele encodes arginine and the (T)
allele encodes the variant histidine (H) [122]. Karassa et al.
[123] conducted a meta-analysis of this polymorphism
across European, African, and Asian populations and con-
ﬁrmed a positive risk to SLE. In general; however, the rela-
tionship has been inconsistent, and a majority of GWAS have
not found signiﬁcant evidence of an association. The excep-
tion is the 2008 GWA by Harley et al. [14] which identiﬁed
an association between rs1801274 but only among European
women.
9.2. FCγR2B. FCγR2B is involved in antibody production
and macrophage activation. Tsuchiya et al. [124] examined
a nonsynonymous SNP within the transmembrane domain,
which was signiﬁcantly associated with SLE in Chinese, Japa-
nese, and Thai populations but was found to be rare in
Europeans. The SNP (rs1050501) led to an aminoacid sub-
stitution within the transmembrane domain at position 232,
isoleucine to tryptophan (I232T). The same group found
that an FCγR2B promoter polymorphism that has been
associated with SLE in Europeans [125] was largely absent in
Asians. In a human B-cell line lacking endogenous FCγR2B,
Kono et al. [126] demonstrated that I232T was less eﬀective
than wild-type at inhibiting B-cell receptor (BCR-) mediated
signaling, and that distribution of FCγR2B to detergent-
insoluble lipid rafts was disrupted. This is supported by
Floto et al. [127], who showed that the lack of inhibition of
activatory receptors resulted in unopposed proinﬂammatory
signaling.
9.3. FCγR3A. Nonsynonymous SNPs in FCγR3A have been
found to alter binding aﬃnities in the four immunoglobulin8 Journal of Biomedicine and Biotechnology
G subclasses. At the SNP rs396991, the (T) allele encodes
phenylalanine (F), and the (G) allele encodes the valine
variant (F158V) [117]. The low-aﬃnity phenylalanine allele
is associated with disrupted immune complex clearance
[128], while the high-aﬃnity valine allele was a strong
predictor of end-stage renal disease [129]. A copy number
variation study by Niederer et al. [130] found signiﬁcant
diﬀerences in FCγR3A and FCγR3B CNV proﬁles between
European, East Asian, and Kenyan populations. Reduced
copy number and homozygosity of FCγR3B were strongly
predictors of SLE susceptibility, but the same association was
n o tr e p o r t e di nr e l a t i o nt oFCγR3A.
9.4. FCγR3B. Three allotypic variants have been identiﬁed
for FCγR3B—NA1, NA2, and SH and are deﬁned by six
SNPs. Hatta et al. [131] report an association between NA2
and SLE, but this has not been replicated (see Yuan et al.
[132]). Nevertheless a number of copy number variation
studies have converged upon the FCγR3B gene as a poten-
tially important locus for SLE susceptibility. These are re-
viewed separately below.
10.InterpretingSLEGWAS
All of the discovery SNPs used to identify the genes listed in
Table 1 have published odds ratios (ORs) between 1.2 and
2.4, with the majority ranking toward the lower end of this
range. This is comparable with GWAS in other autoimmune
disorders including Crohn’s disease [133], rheumatoid arth-
ritis [134], and psoriasis [135] and indeed the GWAS ﬁeld
as a whole. While it is important not to downplay their
signiﬁcance, it should be noted that the predictive value of
such ratios is relatively low [136] and explains less than
15% [137] of the risk for SLE (as would be expected by
GWAS variants all of which are designed to tag LD blocks
showing association). We know from twin and family studies
that the heritability of SLE is approximately 44–69% [138–
140], which means we must consider the problem of missing
heritability. There are a number of possible explanations
between the discordance between the two ﬁgures: (1) SLE is
u n d e r s c o r e db ya ne v e nl a r g e rn u m b e ro fg e n e se a c hc o n -
tributing smaller and smaller proportions of risk variance,
(2) that the variants identiﬁed by GWAS lose signiﬁcant
power in the process of tagging the causative variants, and/or
(3) that the broader SLE phenotype may consist of a several
distinct and rare subtypes. It is also likely that epigenetic
factors are important elements of the missing heritability,
though this is not explored in the current paper.
(1) Gene Networks and Pathway Analysis. The ﬁrst of these
conclusions, that an increasingly larger pool of genes is re-
quired to account for the heritability of SLE, is logical but
complex. The common disease common variant model is
predicatedupontheconclusionthatthecomplexdiseasesare
caused by the interactions of a large network of genes, and
the number of possible causal loci is only constrained by the
number of genes and gene regulators in the human genome.
However, as more and more genes are implicated in this
network,werunintothelawofdiminishingreturns.Pathway
analysis,whichleveragesexistingbiologicalknowledgeabout
gene function to examine how causal factors may interact,
is an attractive mechanism for navigating this law. Pathway-
based approaches typically examine whether test statistics
for a predeﬁned gene-set have concordant (albeit moderate)
deviation from chance. Analyses are based on pathway asso-
ciation approaches in gene expression microarray analysis,
where examination of groups of related genes has yielded
major insights into functional capacity [141, 142].
Ar e c e n ts t u d yf r o mo u rg r o u p[ 5] adopted the pathways
approach to GWAS of Crohn’s disease (CD), which is known
to share certain pathophysiological properties with SLE [37].
The study examined enrichment of association signals for
genes previously identiﬁed as belonging to certain gene
pathway networks, as deﬁned by gene ontology, biocarta
and KEGG, with careful adjustment for gene size, number
of SNPs per each genes, and pathway size. The pathway
that most signiﬁcantly enriched for association signals was
the interleukin-12 gene pathway that harbors the cytokines,
interleukin 12 and 23 (IL-12/IL-23). These share one cellular
receptor subunit and numerous intracellular signaling com-
ponents previously shown to associate with CD [113], to-
gether with multiple other genes associating with CD, for the
ﬁrst time [5]. Indeed, only three genes (IL12B, IL23R,a n d
IL12RB2) at two loci (5q23, 1p31) showed genome-wide sig-
nals in previous studies [113]. However, three further genes
in the IL-12-IL-23 pathway (JAK2, CCR6,a n dSTAT3)w e r e
conﬁrmed as candidate genes in replication studies [109],
and six more genes (including STAT4 and a number of inter-
leukin-coding genes) supported by association in this path-
way have been previously reported as CD susceptibility genes
in other association and functional studies [5, 142–147].
Thus, since only three genes in this pathway have surpassed
the threshold for genome-wide signiﬁcance, we begin to
develop a much richer picture of the pathophysiology of the
disease through the pathway-based approach. This includes
related variants that have remained above signiﬁcance crite-
ria but collectively contribute signiﬁcantly to the risk vari-
ance. Furthermore, given that the strongest candidate gene
is sometimes not the most suitable drug target, the pathway
approach also opens up possible alternatives for targeted
intervention. These interactions are outlined in more detail
in Figure 2. Given the shared etiology between many of the
autoimmune diseases, it is likely that a similar approach
would be productive in extrapolating gene networks in SLE.
(2) Causative Variants and the GWAS Signal. As t u d yf r o m
our group substantiates the second conclusion, that at least
some of the variants tagged by GWAS may actually be tagg-
ing rarer variants that may be responsible for the GWA sig-
nal. This phenomenon is known as synthetic association and
was conﬁrmed in a recent study by Wang et al. [148], who
used sequencing to examine NOD2 as a candidate gene for
CD. Three rare variants (nonsynonymous SNPs) in NOD2,
rs2066844, rs2066845, and rs2066847, had previously been
associated with susceptibility to CD [149, 150], which
had additionally been identiﬁed by functional assays asJournal of Biomedicine and Biotechnology 9
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Figure 2: Linking pathways to disease: Crohn’s disease (from Wang et al. [5]). As an example of how biological pathways are involved in
disease pathogenesis, the authors illustrate a manually compiled pathway centered on IL-12 and IL-23. For each gene, the most signiﬁcant
P value among SNPs close to the gene (based on GWAS) was annotated. Only three genes at two loci (IL12B at 5q33 and IL23R-IL12RB2 at
1p31) showed genome-wide signiﬁcant signals, but three further genes (JAK2, CCR6,a n dSTAT3) in the pathway were conﬁrmed as suscep-
tibility candidates in replication studies. Six further genes in this pathway were reported as Crohn’s disease susceptibility genes by other asso-
ciation and functional studies.
potentially causal [151]. Although NOD2 had not previously
been shown to harbor common causal variants, a 2007 study
by the Wellcome Trust Case Control Consortium (WTCCC)
[152] did implicate a common tag SNP (rs17221417, MAF =
29). From HapMap, we know that the ﬁrst two of the rare
NOD2 variants are in complete linkage disequilibrium with
rs17221417 (the third variant was not listed). A large-scale
meta-analysis of NOD2 estimates the allelic odds ratio (OR)
at between 2.2 to 4.1, which, respectively, explain 0.54%,
1.2%, and 3.4% of genetic risk (5.1% in total). For the com-
mon tag SNP, on the other hand, the OR is 1.37 and ex-
plains on 0.69% of genetic risk for CD. In other words, the
GWA signal dramatically underestimates the proportion of
explained risk at this locus.
A long range haplotype analysis of the GWA data for all
the genes identiﬁed above is therefore recommended. Our
group previously showed that synthetic associations can
cover intervals as long as 2.5-Mb, and include numerous
“blocks” of associated variants [136]. As such, followup and
interpretation of GWA data merit careful deliberation.
Namely,thisapproachmayenrichsamplesetsforindividuals
with rare-causative variants, who should be ﬁltered out from
the cohort and subsequently sequenced for conﬁrmation
[148]. Anderson et al. [153] make the point that certain
GWASsignalsaremoreamenabletothesyntheticassociation
eﬀectthanothers.This includes signals that arefoundincon-
sistently between diﬀerent populations; signals that are not
universally common are more likely to have arisen recently
or been unequally selected for through population history. A
number of the SLE candidate genes reviewed above fall into
this category, including ETS1, ITGAM,a n dBANK1.
(3) Rare Variants. Another source of hidden variance is the
existence of rare phenotypes subsumed under the broader
SLE umbrella but with a separable genetic basis. The hetero-
geneity of the SLE phenotype lends itself to this possibility,
which is also supported by a number of genome sequencing
studies that have emerged in recent years. As mentioned
above, complement defects are present in 1-2% of SLE cases
and represent the strongest single genetic risk factors of
SLE. Additional rare variants associated with SLE include
mutations in the three prime repair exonuclease 1 (TREX1)
gene, which is the most common known cause of monogenic
(i.e., single gene defect) SLE [154, 155] and may be an in-
structive vehicle by which to explore the application of10 Journal of Biomedicine and Biotechnology
sequencing technologies to the disease. Located on chro-
mosome 3p21, TREX1 can metabolize reverse-transcribed
D N Aa n de n c o d e s3   repair exonuclease 1, the primary 3 
to 5  exonuclease in humans. It is a regulator of the IFN-
stimulatory DNA (ISD) response [156], and mutations of
TREX1 can cause Aicardi-Gouti` eres syndrome (AGS) [157],
a severe neurological brain disease that is sometimes comor-
bid with pediatric SLE [158–161]. It is also linked to several
other diseases accelerated atherosclerosis, antiphospholipid
syndrome, and fetal loss [162].
TREX1 mutations in AGS are predominantly recessive
and reduce exonuclease activity. This is the case with a non-
synonymous SNP at position 114 that results in an arginine
to histidine substitution (R114H) [163, 164]. A large-scale
genotyping study of 40 TREX1 SNPs in ∼8370 SLE patients
and ∼7490 controls by Namjou et al. [165] identiﬁed nine
Europeanpatientswithheterozygousmutationsatthislocus,
which was also found in ﬁve European controls. Among
Asians included in the study, two SLE cases had heterozygote
mutations at this locus, but none were found in controls.
Moreover, one Asian case, a male with early-onset SLE, was
found to have a homozygous R114H mutation. The patient,
who also had positive anti-dsDNA antibody, was negative for
neurological manifestations, which are found in AGS chil-
dren with the R114H mutation. A number of other muta-
tions were observed in SLE patients but not respective con-
trols. Among Europeans cases, ﬁve heterozygous mutations
were detected at Y305C but none in controls. Y305C is a mis-
sense coding mutation located outside of the catalytic do-
main. Among Africans, ﬁve cases had a mutation at E266G,
but none were found in controls. Interestingly, this mutation
was also present in Europeans but did not diﬀerentiate cases
from controls. For the SLE group as a whole, the coding
mutation frequency was approximately 0.5%.
Importantly, a case-control association study for com-
mon SNPs did not identify signiﬁcant associations between
the aﬀected and the unaﬀected either for the group as a
whole, or for respective racial groups. This underscores the
point that the association approach is limited in terms of
probing rare variants. However, as discussed above in rela-
tion to CD, GWA signals at the site of a common tag SNP can
prime the locus for followup by sequencing and genotyping.
Th u s ,i nt h eN a m a j o ueta l .s t u d y ,c o m m o nS N P s( d e ﬁ n edb y
a minor allele frequency of 10% or greater) in Europeans
characterized a seizure-associated risk haplotype that was
present in 58% of cases, compared to 45% in controls (P =
0.0008, OR = 1.73, 95% CI = 1.25–2.39).
Although untested, one may speculate that many of the
loci identiﬁed by GWAS may similarly harbor rare variants.
Monogenic subtypes of cutaneous lupus erythematosus (a
rare cutaneous form of lupus erythematosus) have been ob-
served at the TREX1 locus [166]. Similarly, Qari et al. [167]
describe seven Saudi families, where pedigree data is consis-
tent with autosomal recessive Mendelian inheritance. In the
last two years, the application of NGS to monogenic and
oligogenic disorders has accelerated rapidly, reﬂecting the
increased availability of relevant technologies. In our own
group, we have used NGS to indentify the causal variants
in a number of Mendelian phenotypes including rare forms
of Glycogen Storage Disease, familial forms of epilepsy,
hemolytic anemia [168], and Ogden syndrome [169].
Itremainstobeseenwhatproportionofrarevariantswill
account for hidden variance in SLE. Regardless, their study
will continue to play an important role in explicating the
pathogenesis of the disorder. Because rare mutations carry
large eﬀects, they make resolution of underlying networks
distinctly less complex and are also amenable to modeling in
other systems. The widespread application of sequencing
technologies in the clinic will also help characterize and
diﬀerentiate SLE subphenotypes. In this vein, De Vries et al.
[170] used direct sequencing of exonic TREX1 in 60 patients
with neuropsychiatric SLE and identiﬁed a novel heterozy-
gous substitution at position 128 (arginine histidine) in one
case.BecauseTREX1mutationsarealsolinkedtoAGS,which
ischaracterizedbyanumberofneurologicalabnormalities,it
ispossiblethatthisformofSLEsharesacommonpathogenic
mechanism.
11. SLE and Copy Number Variants
The role that rare variants in SLE has is also becoming ap-
parent from a series of copy number variation (CNV) stud-
ies, in the past several years. CNVs are insertions, deletions,
or inversions in the genome that are universal in the gen-
eral population and vary in length from many megabases to
1 kilobase or smaller. Although CNVs per se are not asso-
ciatedwithanyobservablephenotype,theirpresenceingenic
regions has been associated with a number of major diseas-
es, including autism [171], schizophrenia [172, 173], neuro-
blastoma [174], and many others. Arguably the most widely
knownCNVoccursindownsyndrome,whichischaracteriz-
ed by an extra copy of chromosome 21. The origin of most
CNVs is unknown, but causal mechanisms can include re-
plication errors, meiotic recombination, and homologous/
nonhomologous repair of double-strand breaks [175].
Recent studies by the 1000 Genomes Consortium [176]
and Conrad et al. [177] report that common CNVs are well
covered by SNPs in existing arrays and many likely have been
indirectly examined in a range of GWAS. The impact of rare
CNVs, on the other hand, may be substantial. Pang et al.
[178] reexamined data from the Venter genome and iden-
tiﬁed over 12,000 structural variants spanning more than
40Mbofsequence.Thesevariantswerefoundin4,867genes,
which are often large and under negative selection. Because
rarerallelesaremorelikelytohaveahigherpenetrance,these
results strongly support the role of CNVs as causal factors in
genetic diseases. The study also showed that 24% of CNVs
would not be imputed from SNP association alone, which
stressesthepointthatCNVsmaybemoreaccuratelydetected
using the NGS approach.
AnumberofCNVstudieshavehighlightedFCγR3Basan
important locus for CNV diﬀerences between SLE cases and
controls. As outlined above, Fcγ receptors for immunoglob-
ulin G (IgC) are involved in clearing the immune complex,
and many members of the Fcγ have been proposed and
replicated as SLE candidates. As far back as 2006, Aitman
etal.[179]reportedanassociationbetweenlowcopynumberJournal of Biomedicine and Biotechnology 11
in FCγR3B and autoimmune glomerulonephritis in a sub-
sample of 30 individuals with SLE. The same group [180]
replicated this association in 161 Europeans with SLE-
associated glomerulonephritis (control n = 312), as well as
an Afro-Caribbean cohort of 134 patients [181]. This second
study also examined the broader autoimmune disorder phe-
notype (n = 1.279) and found that 25 (2%) have no copies
of FCγR3B. The same analysis of 862 controls indentiﬁed
onlyoneindividualwithnoFCγR3Bcopies.Interestingly,the
group did not observe an association between Graves’ or
Addison’s diseases, both of which are organ-speciﬁc autoim-
mune disorders.
Niederer et al. [130] also described a strong link bet-
ween FCγR3B copy number and identiﬁed a linkage disequi-
librium between FCγR3B and an FCγR2B variant (I232T).
Morris et al. [182] conﬁrmed the association between
FCγR3B low copy number, which was contingent upon allo-
type; SLE risk was greater for NA1 deletion, than deletion
of NA2. The authors also reported a signiﬁcant correlation
between FCγR3B copy number and neutrophil expression
in healthy and control participants. FCγR3B is expressed by
neutrophils and eosinophils. Neutrophils, which mediate in-
ﬂammation responses to host injury [183]a r ea t t r a c t e db y
cytokines at the early stages of infection and also release
cytokines as part of the inﬂammatory response [184]. Eosin-
ophils, also an important part of the inﬂammatory response,
are activated by several cytokines, namely, IL-3, IL-5, and
GM-CSF [185].
CNVshavebeenidentiﬁedatothercandidateSLEloci.In
a study of 532 Asian patients with SLE and 576 controls, Yu
et al. [186] identiﬁed CNVs at IL-12B and T-bet as signiﬁ-
cantly associated with SLE risk. For IL-12B, the frequency of
copy number ampliﬁcation was 63 versus 13 in controls. For
T-bet, the respective values were 46 versus 7. The same group
[187] identiﬁed CNVs at histamine H4 receptor in a cohort
of 340 SLE patients (versus 392 controls). These correlated
with the presence of antinuclear antibody abnormalities, as
well as incidence of arthritis and proteinuria. The group also
identiﬁedCNVenrichmentininterleukins-17F,-21,and-22,
intwoChineseSLEcohorts(Yuetal.[90]).Allelefrequencies
ampliﬁcations for cases versus controls were 107 versus 33,
166 versus 16, and 108 versus 19, respectively. Other studies
have implicated copy number diﬀerences at the TLR7 locus
in women with SLE [188] and at the HIN200 locus in UK
SLE families and French males [189]. Although the majority
of these CNVs are found in only a handful of cases, these
results have broad implications for SLE as a whole and may
collectively account for a relative large proportion of SLE
cases.
12. Conclusions
Taken together, these studies show that SLE is highly heri-
table, and advances in gene-ﬁnding technology in the past
decade have rapidly accelerated gene discovery. Over this
period, a number of themes have begun to emerge: (1) an
ever-increasing catalog of candidate genes that replicate
across diﬀerent studies, (2) a growing list of causal rare
variants, and (3) the emergence of monogenic subtypes.
Monogenic SLE is particularly interesting from a treatment
perspective, as it provides a mechanism for studying the
phenotype in model systems and is a more obvious target
for drug intervention. In order to capitalize upon these
ﬁndings, high-quality phenotype data is required. SLE is
notoriously heterogeneous and is fractionated in terms of
onset, symptoms, and trajectory. The systematic collection
of clinical and biomedical data (e.g., cellular, serological,
and mRNA transcripts) will dramatically increase our ability
to generate testable hypothesis about the contributions of
speciﬁc genes and gene networks to SLE pathophysiology.
Conversely, knowledge of gene function can be used to target
treatments and to predict onset.
Ultimately, the primary goal is not to determine the freq-
uency of variation/mutation in cases versus controls but to
determine the pathways that lead to disease pathology. This
is no simple task, especially when we consider the other
major risk factors such as epigenetics, RNA regulatory ele-
ments, and environmental exposures. While daunting, the
elucidationoftheseelementswilldoubtlesslytakeuscloserto
developing more eﬀective treatments for SLE targeting
selective patients for interventions aimed at restoring the im-
pact from variants within speciﬁc molecular pathways and
gene networks.
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